ea0092ps2-16-01 | Thyroid Cancer clinical 2 | ETA2023
Esposito Gerardo
, Agate Laura
, Lorusso Loredana
, Minaldi Elisa
, Bottici Valeria
, Santi Stefano
, Ribechini Alessandro
, Bruschini Luca
, Elisei Rossella
, Molinaro Eleonora
Lenvatinib is a tyrosine kinase inhibitor (TKI), approved for the management of locally recurrent or metastatic, progressive, radioactive iodine–refractory differentiated thyroid cancer (DTC). A side effect of this drug is the tracheoesophageal fistula, described in 14.7% of patients. When this side effect is present, the interruption/withdrawn of the TKI is required and in this case no valid therapeutic options are described. We present the case of a 63-year-old woman pa...